vs
Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
EVERSPIN TECHNOLOGIES INC. is the larger business by last-quarter revenue ($14.9M vs $7.8M, roughly 1.9× CRYO CELL INTERNATIONAL INC). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -48.7%, a 46.7% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs -2.3%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs -0.1%).
Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
CCEL vs MRAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.8M | $14.9M |
| Net Profit | $-3.8M | $-296.0K |
| Gross Margin | 77.9% | 52.7% |
| Operating Margin | -50.6% | 29.0% |
| Net Margin | -48.7% | -2.0% |
| Revenue YoY | -2.3% | 13.2% |
| Net Profit YoY | -105.1% | — |
| EPS (diluted) | $-0.46 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $7.8M | $14.8M | ||
| Q3 25 | $7.8M | $14.1M | ||
| Q2 25 | $7.9M | $13.2M | ||
| Q1 25 | $8.0M | $13.1M | ||
| Q4 24 | $8.0M | $13.2M | ||
| Q3 24 | $8.1M | $12.1M | ||
| Q2 24 | $8.0M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $-3.8M | $1.2M | ||
| Q3 25 | $749.4K | $54.0K | ||
| Q2 25 | $355.8K | $-670.0K | ||
| Q1 25 | $282.9K | $-1.2M | ||
| Q4 24 | $-1.9M | $1.2M | ||
| Q3 24 | $1.1M | $2.3M | ||
| Q2 24 | $655.8K | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 77.9% | 50.8% | ||
| Q3 25 | 77.0% | 51.3% | ||
| Q2 25 | 76.6% | 51.3% | ||
| Q1 25 | 75.1% | 51.4% | ||
| Q4 24 | 78.4% | 51.3% | ||
| Q3 24 | 73.6% | 49.2% | ||
| Q2 24 | 74.8% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | -50.6% | -7.2% | ||
| Q3 25 | 24.3% | -11.0% | ||
| Q2 25 | 18.8% | -14.9% | ||
| Q1 25 | 13.3% | -14.7% | ||
| Q4 24 | -1.5% | -11.8% | ||
| Q3 24 | 17.2% | -17.5% | ||
| Q2 24 | 17.3% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | -48.7% | 8.1% | ||
| Q3 25 | 9.6% | 0.4% | ||
| Q2 25 | 4.5% | -5.1% | ||
| Q1 25 | 3.5% | -8.9% | ||
| Q4 24 | -23.2% | 9.2% | ||
| Q3 24 | 13.0% | 18.8% | ||
| Q2 24 | 8.2% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $-0.46 | $0.05 | ||
| Q3 25 | $0.09 | $0.00 | ||
| Q2 25 | $0.04 | $-0.03 | ||
| Q1 25 | $0.03 | $-0.05 | ||
| Q4 24 | $-0.23 | $0.07 | ||
| Q3 24 | $0.13 | $0.10 | ||
| Q2 24 | $0.08 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $40.5M |
| Total DebtLower is stronger | $8.4M | — |
| Stockholders' EquityBook value | $-18.6M | $70.2M |
| Total Assets | $61.7M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $3.3M | $44.5M | ||
| Q3 25 | $3.2M | $45.3M | ||
| Q2 25 | $4.4M | $45.0M | ||
| Q1 25 | $3.5M | $42.2M | ||
| Q4 24 | $3.5M | $42.1M | ||
| Q3 24 | $2.1M | $39.6M | ||
| Q2 24 | $1.5M | $36.8M |
| Q1 26 | — | — | ||
| Q4 25 | $8.4M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.4M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $8.5M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $8.5M | — |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $-18.6M | $68.9M | ||
| Q3 25 | $-14.8M | $65.8M | ||
| Q2 25 | $-15.6M | $64.1M | ||
| Q1 25 | $-14.7M | $63.0M | ||
| Q4 24 | $-13.2M | $62.6M | ||
| Q3 24 | $-9.6M | $59.3M | ||
| Q2 24 | $-10.7M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $61.7M | $84.6M | ||
| Q3 25 | $63.2M | $80.3M | ||
| Q2 25 | $64.4M | $78.9M | ||
| Q1 25 | $64.4M | $80.2M | ||
| Q4 24 | $64.7M | $77.8M | ||
| Q3 24 | $62.9M | $72.6M | ||
| Q2 24 | $62.6M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.3M | $570.0K |
| Free Cash FlowOCF − Capex | $1.2M | — |
| FCF MarginFCF / Revenue | 15.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $1.3M | $2.6M | ||
| Q3 25 | $2.5M | $881.0K | ||
| Q2 25 | $707.0K | $5.0M | ||
| Q1 25 | $954.1K | $1.4M | ||
| Q4 24 | $2.2M | $3.8M | ||
| Q3 24 | $2.4M | $2.8M | ||
| Q2 24 | $1.8M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.2M | $-975.0K | ||
| Q3 25 | $2.5M | $543.0K | ||
| Q2 25 | $644.6K | $3.0M | ||
| Q1 25 | $892.0K | $527.0K | ||
| Q4 24 | $2.1M | $2.1M | ||
| Q3 24 | $2.3M | $2.8M | ||
| Q2 24 | $21.5K | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | 15.5% | -6.6% | ||
| Q3 25 | 31.9% | 3.9% | ||
| Q2 25 | 8.1% | 22.9% | ||
| Q1 25 | 11.2% | 4.0% | ||
| Q4 24 | 26.8% | 15.8% | ||
| Q3 24 | 27.9% | 22.9% | ||
| Q2 24 | 0.3% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 24.3% | ||
| Q3 25 | 0.5% | 2.4% | ||
| Q2 25 | 0.8% | 15.1% | ||
| Q1 25 | 0.8% | 6.9% | ||
| Q4 24 | 0.1% | 13.2% | ||
| Q3 24 | 2.3% | 0.5% | ||
| Q2 24 | 21.8% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | 3.38× | 16.31× | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 3.37× | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | 2.32× | 1.25× | ||
| Q2 24 | 2.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCEL
Segment breakdown not available.
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
